Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:06 pm Unchanged |
2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III L.P. | 2,685,448 4.600% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Perceptive Advisors LLC | 2,574,723 4.400% |
-297,824 (-10.37%) |
Filing History |
| 2025-02-14 09:00 am Purchase |
2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
RTW Investments, LP | 3,621,996 6.200% |
1,389,236 (+62.22%) |
Filing History |
| 2024-11-14 5:50 pm Sale |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III L.P. | 2,685,448 5.300% |
-1,049,066 (-28.09%) |
Filing History |
| 2024-11-14 4:33 pm Purchase |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
Perceptive Advisors LLC | 2,872,547 5.700% |
265,868 (+10.20%) |
Filing History |
| 2024-11-14 4:05 pm Purchase |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
Commodore Capital LP | 1,988,084 3.900% |
54,000 (+2.79%) |
Filing History |
| 2024-11-14 09:44 am Sale |
2024-09-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Deep Track Capital, LP | 1,000,000 1.970% |
-1,184,440 (-54.22%) |
Filing History |
| 2024-11-14 09:35 am Sale |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
AVORO CAPITAL ADVISORS LLC | 885,059 1.700% |
-954,079 (-51.88%) |
Filing History |
| 2024-11-12 10:34 am Purchase |
2024-11-08 | 13G | Spyre Therapeutics, Inc. SYRE |
FMR LLC | 7,623,881 14.999% |
1,040,726 (+15.81%) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
BlackRock Inc. BLK |
2,663,147 5.200% |
0 (Unchanged) |
Filing History |
| 2024-10-23 2:10 pm Purchase |
2024-10-14 | 13G | Spyre Therapeutics, Inc. SYRE |
Deutsch Peter E. | 3,550,276 6.990% |
3,550,276 (New Position) |
Filing History |
| 2024-10-22 3:24 pm Purchase |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
BlackRock Inc. BLK |
2,663,147 5.200% |
2,663,147 (New Position) |
Filing History |
| 2024-06-10 09:48 am Sale |
2024-06-07 | 13G | Spyre Therapeutics, Inc. SYRE |
FMR LLC | 6,583,155 12.963% |
-1,020 (-0.02%) |
Filing History |
| 2024-04-25 4:40 pm Purchase |
2024-04-23 | 13D | Spyre Therapeutics, Inc. SYRE |
Fairmount Funds Management LLC | 4,508,579 11.170% |
3,672,120 (+439.01%) |
Filing History |
| 2024-04-23 6:22 pm Sale |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
AVORO CAPITAL ADVISORS LLC | 1,839,138 5.100% |
-286,459 (-13.48%) |
Filing History |
| 2024-03-11 08:19 am Purchase |
2024-03-08 | 13G | Spyre Therapeutics, Inc. SYRE |
FMR LLC | 6,584,175 18.213% |
377,724 (+6.09%) |
Filing History |
| 2024-02-14 8:47 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III L.P. | 3,734,514 9.990% |
3,734,514 (New Position) |
Filing History |
| 2024-02-14 4:51 pm Unchanged |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Nantahala Capital Management, LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:37 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
EcoR1 Capital LLC | 887,076 2.500% |
887,076 (New Position) |
Filing History |
| 2024-02-14 4:27 pm Unchanged |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Perceptive Advisors LLC | 2,606,679 7.200% |
0 (Unchanged) |
Filing History |